AKT pathway activation is implicated in endocrine-therapy resistance. Data on the efficacy and safety of the AKT inhibitor capivasertib, as an addition to fulvestrant therapy, in patients with hormone ...
Effect of NVP-BEZ235, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, on radiosensitivity of oral cancer cell line through G2/M phase checkpoint regulation. This is an ASCO ...
Mechanism of action of p28, a first-in-class, non-HDM2 mediated peptide inhibitor of p53 ubiquitination. This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting I. This abstract does not ...